How Does Novavax Compare to Its Competitors?
Novavax posted a negative EPS (earnings per share) of -$0.39 in 2Q15, which is better than its 1Q15 EPS.
Novavax (NVAX) posted a variety of positive qualitative and quantitative performance indicators in 2Q15.
As per its 2Q15 earnings report, Novavax’s (NVAX) total revenue has gone up by 41.70% from 1Q15 driven by successful clinical tests of new drugs.
To diversify its revenue stream, Celgene is researching its drugs for additional uses in treating lymphoma, chronic lymphocytic leukemia, and anemias.
Since 2014, Celgene has traded at P/E multiples between 13x and 20x. This reflects a strong product portfolio and a high perceived value of research assets.
Celgene’s dependence on geographic expansion exposes the company to increased regulatory risk, while generic competition could lead to revenue declines.
Celgene is collaborating with MedImmune and Juno Therapeutics to develop immuno-oncology drugs and with Acceleron Pharma and OncoMed to explore compounds.
Celgene announced that it will acquire Receptos, a pharmaceutical company, which will add Ozanimod—a drug with high projected peak sales—to its portfolio.
Celgene’s EBITDA margins were lower than those of its competitors. Its R&D investment appears to be higher than its peers, and its SG&A expenses have risen.
Celgene has entered the inflammation and immunology drug market, as well as the cell therapies market, in order to be less dependent on MM drugs.
Celgene is developing drugs for lung cancer and pancreatic cancer, as well, in order to reduce its over-reliance on hematology-related drugs.
Celgene could become a one-stop solution for all MM-related conditions, and it has succeeded in expanding the labels of its existing drugs to include MDS.
As we’ve already discussed in this series, Celgene Corporation (CELG) is focused on the MM (multiple myeloma) cancer drug market.
To reduce its over-reliance on the global multiple myeloma market, Celgene has entered other cancer drug markets, including the anti-inflammatory niche.
Celgene’s Revlimid is the leading second-line therapy for MM. The FDA just approved it as a first-line MM therapy, making Celgene a tough competitor.
Celgene generates revenues primarily through product sales related to multiple myeloma. But it aims to diversify by entering other cancer segments.
Celgene has consistently delivered breakthrough innovations in biotechnology and has as actively pursued acquisitions of companies for access to compounds.
AstraZeneca’s profitability was affected by the 7% decrease in revenues in 2Q15. Net income fell to $697 million in 2Q15. Operating profit margin was 14.6% of revenues at $923 million.
AstraZeneca’s oncology segment is another key focus area. The segment contributed 11.6% in 2014 and 12.1% in 2Q15. Key products for oncology are Zoladex and Faslodex.
AstraZeneca’s RI&A segment is one of the company’s key focus areas of development. The segment contributed nearly 19.2% of total revenues for 2014, which rose to 21% in 2Q15.
But if I knew how to manage my portfolio safer and smarter than most hedge fund managers, I could realistically grow my wealth.